DiNAQOR acquires EHT Technologies: the advisor
DiNAQOR, a gene therapy platform company, announced that it has acquired EHT Technologies , a Germany-based engineered heart tissue (EHT) technology platform company. Financial terms of the transaction were not disclosed.
EHT Technologies was founded in 2015 based upon research on human induced pluripotent stem cells (hiPSC) at the University Medical Center Hamburg–Eppendorf. Cardiomyocytes derived from hiPSC are an innovative research technology for cardiac drug development programs. Engineered heart tissues are three-dimensional, hydrogel-based muscle constructs that can be generated from isolated heart cells of chicken, rat, mouse, human embryonic stem cells and hiPSC. Proof-of-concept studies have shown that EHT can be transduced efficiently with adeno-associated virus (AAV) vectors, including AAV9, validating the use of this platform for gene therapy applications.
Hans Rudolf Trüeb (pictured) Corporate Secretary at DiNAQOR and a Partner at Walder Wyss, advised in this transaction.